1 Background
============

In head and neck cancer treatment and particularly in oral cancer treatment, surgery or radiotherapy alone or radiotherapy in combination with chemotherapy is generally administered. All modalities can lead to significant problems with swallowing and speech with consequent reduction in life quality. The general aim in cancer treatment is to approach maximum tumour control with minimum related side effects. In recent years, chemotherapy has become more relevant and is now an important treatment component in combined modality approaches, several studies in this subject are summarized in \[\[[@B1]\], p. 127\]. Studies, using concurrent chemoradiation in comparison with radiation alone, are commonly randomized trials, which vary in radiation dose, fractionation schedule, and administered chemotherapy. The dosage scheme, which is usually given in mass per body surface area (mg/m^2^), as well as the administration method of the chemical is vital for the prognosis.

Using intra-arterial infusion improved the success of treatment. This is because of the arteries that supply specific tissue, detailed in \[[@B2],[@B3]\]. This technique allows the supply of much higher chemical agent concentration directly to the tumour than intra-venous infusion. The latter, distributes the chemical agent throughout the whole body and causes increased side effects. Because of the patient specific artery geometry and resultant haemodynamics, there is no method that always leads to success, and this is discussed in \[[@B4]\]. The knowledge about the chemical agent concentration in blood and the technique by which the tumours were infused is vital for therapy success \[[@B5]\]. The aim is to supply a high application rate of chemical in a specified target region inside the arterial network.

Advances in computational methods and three-dimensional imaging techniques allow improved understanding of haemodynamic flow in the cardiovascular network. Computational fluid dynamics ([CFD]{.smallcaps}) solves differential equations of fluid flows numerically and is an excellent technique for analysing and displaying blood flow in the head and neck arterial network. In contrast to previous studies \[[@B6]-[@B9]\], using two or three-dimensional ideal geometry, this project deals with real geometry obtained from image-scan segmentation of a patient \[[@B10]-[@B14]\].

Simulation of patient specific two-component flow, using various injection positions and parameters, for instance the mass flow rate of the chemical agent, should deepen the knowledge of chemical agent distribution in the artery network, which is the aim of this study. If an accurate computer simulation is achievable in a sufficiently short time, patient specific computation would provide the basis of comparing the effect of several treatment methods and parameters prior to therapy. A two-component transient [CFD]{.smallcaps} model can assist medical scientists to select the most appropriate treatment strategy.

2 Methods
=========

Considering the pulsatile character of blood flow, a transient [CFD]{.smallcaps} model is required. The model is reduced to the interesting region of the common carotid artery ([CCA]{.smallcaps}) bifurcation, the lingual artery ([LA]{.smallcaps}), facial artery ([FA]{.smallcaps}) and superior thyroid artery ([STA]{.smallcaps}) branch, including two-component flow. In particular the [CFD]{.smallcaps} model comprises the two liquids blood (continuous component or primary phase) and the chemical agent cisplatin (dispersed component or secondary phase). Cisplatin is injected via a catheter into the arterial blood flow. Due to this, the catheter has to be considered as thin pipe inside the [CCA]{.smallcaps}, because the catheter walls cause wall friction and influence the haemodynamic flow pattern.

A patient specific model was created with the image segmentation software Scanip™ \[[@B15]\] from [CT]{.smallcaps}-scans, presented in Figure [1](#F1){ref-type="fig"}. The catheter is an ideal pipe and in clinical practice has an inner diameter of 0.625 mm, an outer diameter of 0.924 mm and the common dose rate is approximately 50 ml/20 s. Four different injection positions are common:

![**Two-component [CFD]{.smallcaps} model considering the cisplatin injection through a catheter, right before the [CCA]{.smallcaps} bifurcation in Figure (a)**. Figure (b) shows the right arterial network and skull source volume model as result of the [CT]{.smallcaps} image segmentation in Scanip™. [APA]{.smallcaps}-ascending pharyngeal artery; [BCA]{.smallcaps}-brachiocephalic artery; [CCA]{.smallcaps}-common carotid artery; [ECA]{.smallcaps}-external carotid artery; [FA]{.smallcaps}-facial artery; [ICA]{.smallcaps}-internal carotid artery; [LA]{.smallcaps}-lingual artery; [RSA]{.smallcaps}-right subclavian artery; [STA]{.smallcaps}-superior thyroid artery; [VA]{.smallcaps}-vertebral artery.](1475-925X-10-104-1){#F1}

• Short before the common carotid bifurcation.

• Internal carotid artery at the height of the superior thyroid branch.

• Lingual shunt.

• Inside the lingual artery.

It was decided to compute the first injection position, because the catheter can be modelled as straight ideal pipe, shown in Figure [1(a)](#F1){ref-type="fig"}. Small pipe geometry creation using few voxels is complicated in Scanip™. Hence, it is impossible to model the catheter entirely including the inner wall in such small dimensions. A catheter outer wall diameter of approximately 1.2 mm (this is 30% larger than the real catheter) and tolerable wall smoothness was achieved with the [CAD]{.smallcaps} primitive generation tools in Scanip™. An additional volume at the top end of the catheter was created to obtain a catheter-blood interface in the following mesh import in Gambit™ \[[@B16]\]. Using the split face tool in Gambit™, this interface was divided by a circle of 0.6 mm diameter and an ideal circular face for the catheter outflow boundary condition was obtained. This face is slightly smaller than the real catheter inner diameter. Since the catheter inner wall is not considered in the model, it was decided to neglect the cisplatin flow inside the catheter entirely and the catheter volume remains unmeshed. Otherwise recirculation would occur inside the catheter near the catheter-blood interface. Additionally the steady ideal pipe flow of cisplatin inside the catheter is entirely solvable with analytical equations.

The mesh consists of hexahedron elements in the vessel core and tetrahedron elements adjacent to walls. A mesh independence test was done in a previous steady simulation on the highest blood flow rate of [CCA]{.smallcaps} using wall *y*^+^and pressure gradient adaption \[[@B17]\]. Due to just slightly monitor data changes after the mesh adaption, the initial mesh of counting 224,115 cells was taken.

A prior one-phase steady cause and effect study was carried out with various Reynolds numbers and viscous models for blood \[[@B17]\]. In this previous study it was discovered that a non-Newtonian material model was compulsory for blood. Comparing the velocity magnitude on diametrical line probes at several outlets, significant lower velocity values were observed for the non-Newtonian models in small arteries, shown in Figure [2](#F2){ref-type="fig"}. In particular, a maximum offset of 20% was computed at the [FA]{.smallcaps} outlet between the Newtonian and the power-law non-Newtonian model due to the very small [FA]{.smallcaps} diameter, approximately 2.9 mm. Moreover, the shear stress transport ([SST]{.smallcaps}) *k*-*ω*turbulence model was found to be appropriate for the whole velocity range and of superior robustness.

![**Velocity profiles over dimensionless vessel diameter with various blood models on a low Reynolds number, taken from our previous study**\[[@B17]\]. Figure (a) shows the [RSA]{.smallcaps} with an approximately diameter of 9.3 mm, Figure (b) shows the velocity profile for the smaller [FA]{.smallcaps} with a vessel diameter of 2.9 mm. The non-Newtonian power-law approach results in lower velocity values, due to more viscosity on low shear rate in the [FA]{.smallcaps} in Figure (b). This effect was not observed in the larger [RSA]{.smallcaps} in Figure (a).](1475-925X-10-104-2){#F2}

The boundary conditions comprise two mass flow inlets, [CCA]{.smallcaps} and catheter, and six outflow outlets with adjusted flow rate weighting. Several measured data dealing with [CCA]{.smallcaps} blood flow pattern is presented in \[[@B18]-[@B21]\]. It is assumed that the additional catheter inlet in the present model does not change the general flow division in the [CCA]{.smallcaps} bifurcation, due to the modelled catheter position still being inside the [CCA]{.smallcaps}. This is not advisable if the injection position moves downstream, for instance to the external carotid artery ([ECA]{.smallcaps}). Unfortunately it is impossible to consider a time dependent flow rate weighting of the [CCA]{.smallcaps} into the [ECA]{.smallcaps} and internal carotid artery ([ICA]{.smallcaps}) in the transient solver of Fluent™ as a boundary condition for each outlet. Hence, only a time averaged flow rate weighting could be used. The time averaged mass loss [(ICA + ECA)/CCA]{.smallcaps} is reported at roughly 5% in \[[@B21]\] and compared with two additional sources in Table [1](#T1){ref-type="table"}. Regarding this 5% to the [STA]{.smallcaps} branch, it is assumed that each branch of the [ICA]{.smallcaps} will have the same proportion of approximately 13.5% of the [ICA]{.smallcaps} mass flow. The time averaged mass flow division was calculated for the [ECA, STA, LA, FA]{.smallcaps} and ascending pharyngeal artery ([APA]{.smallcaps}) outlet and assumed for the [ICA]{.smallcaps} outlet. Figure [3(a)](#F3){ref-type="fig"} provides an overview of the time continuous flow rate weighting for all outflow conditons.

###### 

Measurements of the cycle averaged [CCA]{.smallcaps} rate of flow division in ml/min and the relative outflow/inflow mass loss

  reference    $\overset{˙}{\mathbf{V}}$ [ICA]{.smallcaps}   $\overset{˙}{\mathbf{V}}$ [ECA]{.smallcaps}   $\overset{˙}{\mathbf{V}}$ [CCA]{.smallcaps}   loss
  ------------ --------------------------------------------- --------------------------------------------- --------------------------------------------- ------
  \[[@B21]\]   245                                           125                                           389                                           4.9%
                                                                                                                                                         
  \[[@B32]\]   248                                           95                                            370                                           7.0%
                                                                                                                                                         
  \[[@B33]\]   255                                           95                                            376                                           6.9%

![**Time continuous flow rate weighting off all outlets using the outflow boundary condition in Figure (a)**. The asterisked values are the original time averaged data of \[[@B21]\]. The [CCA]{.smallcaps} flow rate inlet condition in Figure (b) is realized as a transient table with 200 equal distant timesteps (0.0047s timestep size). The cycle time *t~p~*is 0.923s, which is equal to 65 heart beats per minute.](1475-925X-10-104-3){#F3}

The most appropriate data for the [CCA]{.smallcaps} inlet is given in \[[@B21]\] obtained from older volunteers and shown with the solid line in Figure [3(b)](#F3){ref-type="fig"}. However, it can be expected that because of the stress during chemotherapy, the heart rate should be higher than the reported 65 beats per minute in this source. Additionally, the study was made with healthy volunteers. Hence, it is not known how a catheter will affect the reported rate of flow range. These two inlet conditions are converted into a mass flux boundary in the Fluent™ simulation. In particular a transient table for the [CCA]{.smallcaps} and a constant value for cisplatin is used. The volume fraction of the dispersed phase cisplatin was set to 100% at the cisplatin inlet and 0% at the [CCA]{.smallcaps} inlet.

Blood is modelled as a non-Newtonian fluid using the Carreau model (1) with a constant density of *ρ*= 1056 kg/m^3^. The material constants for the haematocrit value of *Ht*= 45% and the temparature of *T*= 310.15 K are given in \[\[[@B22]\], pp. 236-237\]. The maximum Reynolds number of the pulsatile blood flow is 856, which indicates laminar blood flow through the whole cycle.

$$\begin{matrix}
{\mu\left( \overset{˙}{\gamma} \right) = \mu_{\infty} + \left( {\mu_{0} - \mu_{\infty}} \right)\left\lbrack \left. 1 + \left( {\lambda_{t}\overset{˙}{\gamma}} \right)^{2} \right\rbrack \right.^{{({n - 1})} \slash 2},} \\
{\textsf{where}\quad\mu_{0} = 0.056\mspace{500mu}\textsf{Pa~s},\quad\mu_{\infty} = 0.00345\mspace{500mu}\textsf{Pa~s},} \\
{\lambda_{t} = 3.313\;\textsf{s},\quad n = 0.3568.} \\
 \\
\end{matrix}$$

The Newtonian material model was used for cisplatin with properties of water, *ρ*= 998.2 kg/m^3^and *μ*= 0.001003 Pa s.

The Reynolds number of the steady cisplatin flow inside the catheter is 5331. This is far above the commonly known threshold for laminar pipe flow *Re*= 2300. Turbulence is considered through the [SST]{.smallcaps}*k*-*ω*model. At the laminar [CCA]{.smallcaps} inlet *k*and *ω*is set to 0. At the turbulent cisplatin inlet on top of the catheter *k*= 0.359 m^2^/s^2^and *ω =*26165 s ^-1^, determined by using an approach for fully developed turbulent pipe flows (2) dealt with in \[\[[@B16]\], ch. 7.2.2\].

$$\begin{matrix}
{k = \frac{3}{2}\left( {u_{mag} \cdot I} \right)^{2}\quad\textsf{with}\quad I = 0.16 \cdot Re^{- \frac{1}{8}},} \\
{\omega = \frac{k^{1 \slash 2}}{C_{\mu}^{1 \slash 4} \cdot l_{T}}\quad\textsf{with}\quad C_{\mu} = 0.09\quad\textsf{and}\quad l_{T} = 0.07 \cdot d_{h}.} \\
 \\
\end{matrix}$$

All walls are rigid and a non-slip condition is prescribed. The mixing model was used including slip velocity and implicit body force effects. Assuming a bubble size of 0.1 mm for the dispersed phase cisplatin, a hydraulic diameter of *d~h~*= 6 mm for the [CCA]{.smallcaps} and a maximum blood velocity of 0.8 m/s, a Stokes number of 0.021 was calculated using the equations (3), dealt with in \[\[[@B23]\], p. 194\]. This is much smaller than one and means that all cisplatin bubbles will closely follow the blood flow. A strong coupling between blood and cisplatin is supposed.

$$St = \frac{\tau_{d}}{\tau_{c}}\quad\textsf{with}\quad\tau_{d} = \frac{\rho_{d} \cdot {d_{d}}^{2}}{18\mu_{c}}\quad\textsf{and}\quad\tau_{c} = \frac{d_{h}}{u_{mag}}$$

After testing one initial cycle using 100 time steps, the transient simulation proceeded in batch mode using 200 equal distant time steps for one additional cycle. Double precision, first order discretization and the pressure based segregated [PISO]{.smallcaps} solver including skewness and neighbour correction of one, were used with a convergence criteria of 1 · 10^-7^for the cisplatin volume fraction residual. All other settings remained at Fluent™ default values. Data for each 10 th time step was saved. The computing time required approximately four days, shared by three parallel processors.

3 Results and discussion
========================

Figure [4(a)](#F4){ref-type="fig"} shows vectors of velocity magnitude in several cross sections coloured by the turbulent kinetic energy *k*in the time step with the highest blood volume flow rate. The catheter inlet vectors are not exactly perpendicularly aligned with the catheter axis. The cisplatin flow is frontal orientated towards the inner wall of the [CCA]{.smallcaps} bifurcation with a small incline towards the [ECA]{.smallcaps}. Creation of the catheter geometry in [CAD]{.smallcaps} software would be useful to obtain a proper plain catheter front surface. This would be perpendicular, ideally cylindric and the catheter wall would be smooth. Because of the turbulent Reynolds number inside the catheter, turbulence is introduced in the blood flow through the cisplatin inlet. And it occurs at both inner walls after the [CCA]{.smallcaps} bifurcation in the [ICA]{.smallcaps} and [ECA]{.smallcaps}. Sutera and Mehrjardi \[[@B24]\] reported in their study that the red blood cells deform gradually toward a smooth ellipsoidal shape by the alternation of the magnitude in the shear stress from 10 Pa to 250 Pa. The region of fluctuating stresses associated with high turbulent kinetic energy, that indicates high turbulence and is shown in Figure [4(b)](#F4){ref-type="fig"}, is therefore critical in matters of red blood cell damage (haemolysis), thrombosis (blood clotting) or even a stroke. Additionally, the [CCA]{.smallcaps} bifurcation is known as region with a high possibility of arteriosclerosis for elderly patients. The turbulent cisplatin flow could have an abrasive effect and release fatty particles.

![**In (a) vectors of velocity magnitude coloured by turbulent kinetic energy *k*are presented (range above the colour bar)**. The catheter on the right is displaced from its origin in the [CCA]{.smallcaps} centre. The mean velocity at [CCA]{.smallcaps} inlet is 0.38 m*s*^-1^and at cisplatin inlet 7.66 m*s*^-1^. Figure (b) shows the related contour plot of *k*. Figure (c) and (d) are plots of wall shear stress in systole and diastole (range below the colour bar).](1475-925X-10-104-4){#F4}

Furthermore, in consequence of the frontal orientated cisplatin inlet stream towards the [CCA]{.smallcaps} bifurcation wall, the wall shear stress shows a peak (≈ 80 Pa) in this region, presented in Figure [4(c)](#F4){ref-type="fig"} and [4(d)](#F4){ref-type="fig"} for systole and diastole, respectively. This level of high wall shear stress can potentially cause acute vascular endothelial changes as it was found in \[[@B25]\] that the acute yield stress is approximately 37.9 Pa.

Due to the toxic properties of cisplatin, this catheter outflow position can cause several complications, such as local inflammation and neurological complications, for instance headache and facial paresis, \[[@B3]\].

The cisplatin distribution during one cardiac cycle can be described in detail by using Figure [5](#F5){ref-type="fig"}. In general, the chemical agent cisplatin distributes in all arteries, as to be expected for this catheter position. This is undesirable, because only a high cisplatin concentration in a specific region gives maximum tumour control with minimum related side effects. Prior systole, the path lines indicate recirculation upstream in the [CCA]{.smallcaps}. The cisplatin volume fraction in the [ECA]{.smallcaps} is larger than in the [ICA]{.smallcaps}. This is explained by the flow rate weighting conditions of Figure [3(a)](#F3){ref-type="fig"}. With the start of systole and increasing blood flow, the cisplatin concentration decreases in the larger arteries [ECA]{.smallcaps} and [ICA]{.smallcaps}, Figure [5 (c)-(e)](#F5){ref-type="fig"}, and the recirculation region disappears. There is a time shift in cisplatin volume fraction reduction to note between [ECA]{.smallcaps} and [LA]{.smallcaps} with [FA]{.smallcaps}. This is shown in Figure [5(d)](#F5){ref-type="fig"}. This shift is retained until the beginning of the diastole in Figure [5(f)](#F5){ref-type="fig"} when the volume fraction in [ECA, LA]{.smallcaps} and [FA]{.smallcaps} are approximately equal. At the end of diastole in Figure [5(g)](#F5){ref-type="fig"} a similar condition is observed as in Figure [5(a)](#F5){ref-type="fig"}. This suggests a periodic cisplatin distribution characteristic controlled by the cardiac cycle. It also shows the importance of considering a pulsatile blood flow boundary condition. If the simulation was steady, a delay in cisplatin concentration at various artery limits would be invisible in the simulation results.

![**Path lines with origin cisplatin inlet coloured by volume fraction of cisplatin during one cardiac cycle**. The catheter is hidden. The blood flow condition at the [CCA]{.smallcaps} inlet is shown in each picture on the bottom left.](1475-925X-10-104-5){#F5}

The mass weighted average cisplatin volume fraction for all 21 saved time steps at all model outlets is presented in Figure [6](#F6){ref-type="fig"}. The discussed delay of cisplatin concentration between [ICA]{.smallcaps} and [LA]{.smallcaps} with [FA]{.smallcaps} is good to observe. In particular, the functions of [ICA, ECA, STA]{.smallcaps} and [APA]{.smallcaps} show a qualitatively similar shape contrary to the functions of [LA]{.smallcaps} and [FA]{.smallcaps}. Apart from the [ICA]{.smallcaps} all arteries have an approximately equal cisplatin concentration range between 0.3 and 0.5. It is not expected that a variation in cisplatin dosage will change this uniform distribution, rather a catheter position further downstream could have a positive effect in this matter.

![**Mass weighted average cisplatin volume fraction at the outlets over one cardiac cycle**.](1475-925X-10-104-6){#F6}

Additionally, the time dependent cisplatin concentration functions, observed for all outlets, indicate that the time continuous boundary condition at the cisplatin inlet is not the most efficient technique for applying high chemical agent dosages. It is possible that an unsteady injection at a particular beneficial time range on higher dosage rate could enhance the cisplatin concentration and reduce side effects, such as local inflammation at artery walls, during the remaining period. An advantageous time range for injection would be between *t*/*t~p~*= 0-0.3 during peak systole. Furthermore, it is possible that recirculation and the exposure time on high turbulence could be reduced by time dependent injection during systole. Future simulations are required to provide evidence for this assumptions. In absolute values, Figure [7](#F7){ref-type="fig"} represents the rate of flow of the chemical. The prescribed flow rate weighting is the reason for the low level of [STA, LA, FA]{.smallcaps} and [APA]{.smallcaps} compared with [ECA]{.smallcaps} and [ICA]{.smallcaps}.

![**Cisplatin rate of flow at the outlets**. Figure (b) shows the outlets [STA, LA, FA]{.smallcaps} and [APA]{.smallcaps} of Figure (a) separately with a finer ordinate resolution.](1475-925X-10-104-7){#F7}

4 Conclusions
=============

The distribution and concentration of the chemical agent cisplatin have been investigated in a realistic three dimensional patient specific geometry of human head and neck arteries. The used injection position gives an ineffective cisplatin division. This means that the chemical agent is distributed in all arteries and not in one specific tumour feeding artery, a fact of great importance. High wall shear stress and turbulence near the [CCA]{.smallcaps} bifurcation inner walls can cause serious harm, for instance acute vascular endothelial changes or haemolysis. It should be expected that an injection position in the core of the artery further downstream would reduce this high exposure. The time continuous cisplatin inlet condition seems to be ineffective during diastole, when upstream recirculation in the [CCA]{.smallcaps} mainly occurs. It should be investigated if a time dependent injection during the advantageous systole would lead to an equal cycle averaged cisplatin concentration with reduced side effects caused by the catheter inflow.

In blood flow [CFD]{.smallcaps} simulation using multiphase models, neither mass flow nor velocity outlets are practicable, due to required outlet data for each phase. This data is unknown a priori for the secondary phase cisplatin and is the aim of this simulation. An assumed flow rate weighting was used in this model based on measured data for the two main outlets [ICA]{.smallcaps} and [ECA]{.smallcaps}. It is assumed that the general blood flow division remains unchanged in comparison with measured data of healthy volunteers in the normal state. An injection position further downstream in a side branch of the [ECA]{.smallcaps} would probably change the blood flow division. An alternative proper methodology would be to use the pressure inlet and outlet boundary conditions, that require only the volume fraction of the secondary phase at the inlets, and adjust the pressure to a correct level. However, time dependent pressure functions for each model boundary were not available and are difficult to assess for small arteries, such as the [LA]{.smallcaps} and [FA]{.smallcaps}. The implementation of an arterial one dimensional model seams to be the superior way for future [CFD]{.smallcaps} simulations dealt with in \[[@B26]-[@B31]\].
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